Marksans Pharma Stock Screener | Share Price & Fundamental Analysis
MARKSANS
Pharmaceuticals
Screen Marksans Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹182.76
▲
3.49 (1.95%)
Share Price BSE
₹182.45
▲
3.30 (1.84%)
Market Cap
₹8,294.73 Cr.
P/E Ratio (TTM)
23.00
P/B Ratio
3.02
EPS (TTM)
₹8.40
Dividend Yield
0.45%
Debt to Equity
0.12
52W High
₹274.95
52W Low
₹164.41
Operating Margin
20.00%
Profit Margin
13.34%
Revenue (TTM)
₹742.00
EBITDA
₹166.00
Net Income
₹99.00
Total Assets
₹3,240.00
Total Equity
₹2,489.00
Marksans Pharma Share Price History - Stock Screener Chart
Screen MARKSANS historical share price movements with interactive charts. Analyze price trends and patterns.
Marksans Pharma Company Profile - Fundamental Screener
Screen Marksans Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MARKSANS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE750C01026
Marksans Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen MARKSANS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 3,240 | 2,681 | 2,190 | 1,640 | 1,229 | 903 | 804 | 729 | 752 | 722 |
| Current Assets | 2,204 | 1,863 | 1,675 | 1,201 | 903 | 594 | 531 | 449 | 484 | 440 |
| Fixed Assets | 982 | 776 | 486 | 428 | 309 | 303 | 270 | 279 | 267 | 270 |
| Liabilities | ||||||||||
| Total Liabilities | 3,240 | 2,681 | 2,190 | 1,640 | 1,229 | 903 | 804 | 729 | 752 | 722 |
| Current Liabilities | 273 | 205 | 84 | 61 | 25 | 25 | 18 | 16 | 16 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 2,489 | 2,086 | 1,765 | 1,223 | 905 | 649 | 553 | 480 | 440 | 463 |
| Share Capital | 45 | 45 | 45 | 41 | 41 | 41 | 41 | 41 | 41 | 53 |
| Reserves & Surplus | 2,422 | 2,020 | 1,700 | 1,068 | 846 | 595 | 502 | 430 | 393 | 401 |
Screen MARKSANS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 742 | 626 | 724 | 710 | 642 | 606 | 577 | 591 | 550 | 510 | 497 | 498 | 467 | 450 | 433 |
| Expenses | 576 | 520 | 582 | 543 | 495 | 462 | 450 | 453 | 417 | 398 | 376 | 403 | 372 | 361 | 354 |
| EBITDA | 166 | 106 | 142 | 167 | 147 | 143 | 126 | 138 | 133 | 112 | 121 | 94 | 94 | 89 | 79 |
| Operating Profit % | 20.00% | 16.00% | 18.00% | 20.00% | 23.00% | 22.00% | 20.00% | 23.00% | 21.00% | 20.00% | 23.00% | 16.00% | 18.00% | 17.00% | 15.00% |
| Depreciation | 27 | 23 | 23 | 21 | 20 | 20 | 21 | 22 | 18 | 14 | 14 | 13 | 14 | 11 | 21 |
| Interest | 6 | 6 | 3 | 3 | 3 | 3 | 5 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 5 |
| Profit Before Tax | 133 | 77 | 116 | 143 | 125 | 120 | 100 | 113 | 114 | 97 | 104 | 79 | 78 | 76 | 53 |
| Tax | 34 | 18 | 25 | 38 | 27 | 31 | 23 | 30 | 30 | 26 | 22 | 17 | 18 | 16 | 23 |
| Net Profit | 99 | 58 | 91 | 105 | 98 | 89 | 78 | 83 | 84 | 70 | 83 | 62 | 60 | 60 | 30 |
| EPS | 2.17 | 1.29 | 2.00 | 2.31 | 2.13 | 1.96 | 1.73 | 1.84 | 1.84 | 1.52 | 1.97 | 1.56 | 1.52 | 1.46 | 0.69 |
Marksans Pharma Cash Flow Screener - Liquidity Fundamentals
Screen MARKSANS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 207 | 230 | 237 | 99 | 179 | 233 | 27 | 50 | 14 | 31 |
| Investing Activities | -49 | -141 | -259 | -84 | -45 | -60 | -14 | -39 | -21 | -123 |
| Financing Activities | -65 | -69 | 198 | 80 | -15 | -114 | -21 | 3 | -4 | -58 |
| Net Cash Flow | 93 | 21 | 176 | 94 | 119 | 60 | -7 | 15 | -10 | -150 |
Screen MARKSANS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 43.87% | 43.87% | 43.87% | 43.85% | 43.87% | 43.87% | 43.87% | 43.85% |
| FII Holding | 22.20% | 19.88% | 16.92% | 15.57% | 18.60% | 21.31% | 21.96% | 10.88% |
| DII Holding | 4.56% | 5.50% | 5.28% | 5.17% | 3.75% | 4.10% | 4.30% | 1.46% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 25.77% | 26.75% | 29.53% | 30.91% | 29.47% | 26.77% | 26.24% | 34.42% |
| Other Holding | 3.59% | 4.00% | 4.40% | 4.49% | 4.31% | 3.95% | 3.63% | 9.39% |
| Shareholder Count | 257,273 | 256,221 | 265,788 | 254,699 | 235,500 | 248,845 | 259,813 | 198,382 |
Marksans Pharma Dividend Screener - Share Yield Analysis
Screen MARKSANS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.80 | 0.45% |
| 2024-March | ₹0.60 | 0.27% |
| 2023-March | ₹0.50 | 0.33% |
| 2022-March | ₹0.25 | 0.34% |
| 2021-March | ₹0.25 | 0.55% |
| 2020-March | ₹0.10 | 0.20% |
| 2019-March | ₹0.05 | 0.36% |
| 2018-March | ₹0.05 | 0.20% |
| 2017-March | ₹0.05 | 0.16% |
Marksans Pharma Index Membership - Market Screener Classification
Screen MARKSANS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Marksans Pharma Market Events Screener - Corporate Actions
Screen MARKSANS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.60 /share | 73.31% | ||
| Dividend | ₹ 0.25 /share | -3.92% | ||
| Annual General Meeting | NA | 50.49% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 9.28% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -11.45% |
| 2025-08-08 | 2025-08-08 | Annual General Meeting | NA | -16.51% |
| 2025-08-01 | 2025-08-01 | Dividend | ₹ 0.80 /share | -5.63% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 7.03% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 3.18% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 8.46% |
| 2023-06-07 | 2023-06-07 | Dividend | ₹ 0.50 /share | 18.20% |
| 2022-08-19 | 2022-08-23 | Dividend | ₹ 0.25 /share | 8.78% |
Marksans Pharma Competitors Screener - Peer Comparison
Screen MARKSANS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 425,402 | 40.28 | 54,729 | 9.71% | 10,980 | 53.13 |
| Divis Laboratories | 175,979 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 137,697 | 62.26 | 11,539 | 6.99% | 1,911 | 71.28 |
| Cipla | 118,419 | 22.75 | 28,410 | 7.12% | 5,291 | 57.84 |
| Dr Reddys Laboratories | 103,886 | 18.27 | 33,741 | 16.73% | 5,725 | 46.16 |
| Lupin | 100,720 | 22.61 | 22,910 | 13.74% | 3,306 | 63.46 |
| Mankind Pharma | 94,929 | 52.17 | 12,744 | 20.90% | 2,007 | 56.13 |
| Zydus Life Science | 93,187 | 18.63 | 23,511 | 18.55% | 4,615 | 54.52 |
| Aurobindo Pharma | 72,008 | 20.91 | 32,346 | 9.43% | 3,484 | 60.21 |
| Alkem Laboratories | 69,599 | 28.04 | 13,458 | 3.70% | 2,216 | 55.49 |
Marksans Pharma Company Announcements - News Screener
Screen MARKSANS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-26 | Closure of Trading Window | View |
| 2025-11-21 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-20 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-17 | Newspaper Publication Of Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-13 | Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025 | View |
| 2025-11-13 | Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025 | View |
| 2025-11-10 | Observance Of Vigilance Awareness Week 2025 At Marksans Pharma Limited | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-03 | DISCLOSURE REGARDING 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK" | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-27 | ESG Score By CFC Finlease Private Limited (Voluntary) | View |
| 2025-10-23 | Board Meeting Intimation for Declaration Of Quarterly Results For The Quarter And Nine Months Ended September 30 2025 | View |
| 2025-10-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |